BNTXBioNTech SESigning up patients
A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 105 (planned)
- Started
- Dec 4, 2025
- Main results expected
- Dec 2027
- Fully finished
- Aug 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed overall response rate
Measured over: Up to 24 months
Occurrence of treatment emergent adverse events (TEAEs) by severity
Measured over: From the first dose of study treatment until 90 days after the last dose of study treatment (up to 32 months).
Occurrence of dose interruptions, reductions, and discontinuations due to TEAEs
Measured over: Up to 24 months after first dose
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07255404 · record last updated 2026-07-28 · checked 2026-11-09 15:47 UTC